The hypoxic tumour microenvironment brought about by antiangiogenic agents (such as bevacizumab and cediranib) is thought to downregulate the expression of key gene products involved in homologous recombination repair (BRCA1/2 and RAD51) [114]. This evidence concerns the gene BRCA1 and neoplasm.